Diligence memo · auto-generated · as of July 2, 2026
Aspargo Laboratories, Inc.
Aspargo Laboratories, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Aspargo Laboratories, Inc. operates in Pharmaceuticals, based in ENGLEWOOD CLIFFS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aspargo Laboratories, Inc. has raised $9.7M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.9M on 2020-02-02.
Most recent recorded round closed around 2022-11-28.
Valuation (modeled)modeled
Provath models Aspargo Laboratories, Inc. at approximately $3.1M (range $332K–$9.5M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.09× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era. Issuer reports $0–$1M revenue while modeled below niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 3.6 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 5.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 53% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 5% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.